"VISITORS ARE ADVISED TO ALSO CHECK OUT THE CO-RELATED ADS DISPLAYED BELOW TO HAVE ADDITIONAL KNOWLEDGE ON THE SUBJECT. YOUR SINCERE EFFORT WOULD HELP US TO SERVE YOU BETTER".

My View on Dr Reddy


About The Company

The company is engaged in medicine business . Dr Reddy's , Ranbaxy and Cipla are some of the market leaders in this segment. The stock has been fancied among the investor for long time in the capital market.

About The Results


The company has posted result for the last quarter with a PAT at Rs.192 crore. The earnings would have been much higher but for the lower earnings from Europe fell due to declining prices, affecting the margins. But on the other hand, its sales in USA more than quadrupled due to the launch of its new generic drug Sumatriptan, used for treating acute migrane.


Overall revenues were up 49% on a YoY at Rs. 1840 crore. EBITDA was up 58%. Net profit was at Rs.192.0 crore as against a net loss of Rs.121.30 crore it posted in Q3FY08. What is commendable is that it posted a net forex loss of Rs 49.3 crore as against a net gain of Rs. 8.7 crore in Q3FY08. The forex loss was mainly on account of fluctuations of Russian Rouble.


Germany continues to remain a problem region. The withdrawal of Olanzapine stocks due to upholding of patent validity by a German court and price decline pulled down the margins. Its AOK tender too is entangled in legal problems and the company has said that a better profitability picture from Germany would emerge only in Q4.

Dr Reddy’s launched 10 new products during the quarter and it plans to launch two biologics products during next fiscal in the domestic market. For FY10, the company has projected a flat growth as a lot of its growth depends on the outcome of its tenders in Germany.


About The Stock

The stock has been evergreen performer but some pain is yet left and need to be over before fresh buying in this counter.

Disclaimer : I do not have any personal holding in this company.